Jefferies analyst Eun Yang views Rigel Pharmaceuticals' restructuring, which prioritizes fostamatinib commercialization while reducing research workforce, as a positive. The analyst notes the move will have no impact on the company's early programs. She raised her price target for Rigel shares to $9 from $8.50 and keeps a Buy rating on the name. Rigel closed yesterday up 4c to $3.45. The next major catalyst for the stock will be second Phase 3 data for fostamatinib in Immune Thrombocytopenic Purpura in October or November, Yang tells investors in a research note. She expects additional indications opportunities to drive "meaningful share price appreciation."